https://jim.bmj.com/content/68/6/1156
https://pubmed.ncbi.nlm.nih.gov/32606041/?utm_source=MS-Office&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1XWEJfKtgOH5BJCB_XVnY7XwqtC08V0cBeD29-y2snwFvl-1ex&fc=20200619141551&ff=20200701120504&v=2.9.5
Bupropion in the treatment of postural orthostatic tachycardia syndrome (POTS): a single-center experience
Postural orthostatic tachycardia syndrome (POTS) is estimated to impact millions of people each year. However, there is no established gold standard for its treatment. Bupropion is a norepinephrine and a dopamine reuptake inhibitor and has been implicated as a potential treatment for POTS. We performed a non-randomized retrospective chart review on 47 patients with POTS with statistical analysis evaluating for significant findings including reduced orthostasis and improvement of symptoms with…
pubmed:32606041
pmid:32606041,doi:10.1136/jim-2020-001272
Date Found:
Wed, 01 Jul 2020 06:00:00 -0400
